Creative Planning
MRNA icon

Creative Planning’s Moderna MRNA Stock Holding History

Creative Planning’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.35M Buy
90,670
+3,761
+4% +$195K ﹤0.01% 1215
2026
Q1 		$4.41M Buy
86,909
+6,587
+8% +$307K ﹤0.01% 1304
2025
Q4 		$2.37M Sell
80,322
-14,617
-15% -$397K ﹤0.01% 1594
2025
Q3 		$2.45M Sell
94,939
-12,654
-12% -$353K ﹤0.01% 1376
2025
Q2 		$2.97M Buy
107,593
+17,519
+19% +$461K ﹤0.01% 1042
2025
Q1 		$2.55M Sell
90,074
-1,304
-1% -$46.3K ﹤0.01% 1024
2024
Q4 		$3.8M Buy
91,378
+45,957
+101% +$2.2M ﹤0.01% 777
2024
Q3 		$3.04M Sell
45,421
-8,594
-16% -$789K ﹤0.01% 858
2024
Q2 		$6.41M Sell
54,015
-2,944
-5% -$373K 0.01% 542
2024
Q1 		$6.07M Buy
56,959
+8,804
+18% +$887K 0.01% 549
2023
Q4 		$4.79M Sell
48,155
-30,017
-38% -$2.52M 0.01% 579
2023
Q3 		$8.07M Buy
78,172
+39,072
+100% +$4.36M 0.01% 406
2023
Q2 		$4.75M Sell
39,100
-5,275
-12% -$704K 0.01% 538
2023
Q1 		$6.82M Sell
44,375
-5,695
-11% -$939K 0.01% 425
2022
Q4 		$8.99M Sell
50,070
-5,816
-10% -$951K 0.01% 351
2022
Q3 		$6.61M Sell
55,886
-3,104
-5% -$471K 0.01% 384
2022
Q2 		$8.43M Buy
58,990
+8,103
+16% +$1.16M 0.01% 350
2022
Q1 		$8.77M Buy
50,887
+16,104
+46% +$2.71M 0.01% 338
2021
Q4 		$8.83M Buy
34,783
+73
+0.2% +$21.3K 0.01% 310
2021
Q3 		$13.4M Buy
34,710
+18,593
+115% +$6.86M 0.02% 223
2021
Q2 		$3.79M Sell
16,117
-35,923
-69% -$6.42M 0.01% 481
2021
Q1 		$6.82M Sell
52,040
-5,274
-9% -$764K 0.01% 345
2020
Q4 		$5.99M Buy
57,314
+9,596
+20% +$971K 0.01% 338
2020
Q3 		$3.38M Buy
47,718
+1,175
+3% +$81.9K 0.01% 403
2020
Q2 		$2.99M Sell
46,543
-1,853
-4% -$101K 0.01% 384
2020
Q1 		$1.45M Buy
+48,396
New +$1.11M 0.01% 526

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Creative Planning's MRNA Position: Q2 2026 in Review

Creative Planning increased its Moderna (MRNA) stake by 4.3% in Q2 2026, buying an estimated $195K and bringing the position to 90,670 shares worth $6.35M. The position accounts for ﹤0.01% of the portfolio, ranked #1215.

Creative Planning first reported a position in MRNA in Q1 2020 and has held it in 26 quarters since. The position peaked at $13.4M in Q3 2021. 782 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • Creative Planning held 90,670 shares of Moderna worth $6.35M as of Q2 2026.
  • Creative Planning bought 3,761 Moderna shares in Q2 2026, an estimated $195K.
  • Moderna made up ﹤0.01% of Creative Planning's portfolio in Q2 2026, its #1215 holding.
  • Creative Planning first reported a position in Moderna in Q1 2020 and has held it in 26 quarters since.
  • Creative Planning's Moderna position peaked at $13.4M in Q3 2021.
  • 782 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Creative Planning's 13F filing for Q2 2026, filed 13 Aug 2026.